Qili Chu

机构：Arrowhead Pharmaceuticals (United States) · ORCID：0000-0002-4935-3283

发表论文 43 篇 · 总被引 1872 次 · h-index 18

代表论文

• Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes (2007 · Proceedings of the National Academy of Sciences · 被引 679)
• Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection (2013 · Molecular Therapy · 被引 292)
• Co-Injection of a Targeted, Reversibly Masked Endosomolytic Polymer Dramatically Improves the Efficacy of Cholesterol-Conjugated Small Interfering RNAs In Vivo (2012 · Nucleic Acid Therapeutics · 被引 100)
• Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease (2020 · JCI Insight · 被引 59)
• Comparison of the effects of caudal pole hemi-meniscectomy and complete medial meniscectomy in the canine stifle joint (2004 · American Journal of Veterinary Research · 被引 48)
• Protease-triggered siRNA delivery vehicles (2015 · Journal of Controlled Release · 被引 40)